VRC and Calcbench Collaborate on Goodwill Impairment Video
VRC and Calcbench collaborate as part of an ongoing commitment to educating the industry on complex buy important financial measurement and reporting topics.
The Current State of Goodwill & Impairments
A video discussion about corporate goodwill, goodwill impairment, and financial analysis techniques that aid in determining if a business combination is living up to performance expectations.
VRC to Present at Workiva Amplify Conference
Kevin Hagemeier and Dan Peterson will present at the Workiva Amplify conference in Dallas.
First, Do No Harm
Opinion: The FASB is soliciting feedback on whether and how to further simplify the accounting for goodwill and intangible assets for public companies. This may be setting off down a harmful course of accounting treatment.
How to Win Your Fantasy Football League in 2019? Use Valuation Methodologies!
Want to crush your fantasy football championship this year? Take a page out of a valuation professional’s playbook.
DACH & European Capital Market Study
The latest editions of the DACH Capital Market Study and the European Capital Market Study are now available from our international affiliate partner, ValueTrust.
Industry Update: IT Government Contracting
Just released! Read VRC’s latest Industry Update on IT Government Contracting for relevant market data, trends in EBITDA multiples, notable deals and more.
Patel, Falcon, Mellen and Pumphrey to Present at Joint ASA Conference
The joint ASA conferences will feature sessions and social events that will provide attendees the opportunity to expand their global professional network and explore the latest ideas, trends and best practices with fellow professionals in the valuation and appraisal communities.
Understanding Tax Amortization Benefit Considerations and the International Impact
Tax amortization benefit rules differ between countries, and they can also change over time.
Mainville Quoted in Private Funds CFO
The International Private Equity Venture Capital Valuation Guidelines recently removed the at-investment cost as a stand-alone tool to calculate fair value, leaving GPs with a number of questions.